Anmelden Kostenlos registrieren

ProMIS Neurosciences Beta

Was ist das Beta von ProMIS Neurosciences?

Beta von ProMIS Neurosciences, Inc. ist 0.71

Was ist die Definition von Beta?



BETA gibt an, ob eine Aktie mehr oder weniger schwankungsanfällig ist als der Gesamtmarkt. Ein Beta von weniger als 1 zeigt an, dass die Aktie weniger schwankungsanfällig ist als der Markt, während ein Beta von mehr als 1 anzeigt, dass die Aktie mehr schwankungsanfällig ist. Die Schwankungsanfälligkeit wird als Schwankung des Preises um den Mittelwert gemessen.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta von Unternehmen in Health Care Sektor auf TSX im Vergleich zu ProMIS Neurosciences

Was macht ProMIS Neurosciences?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Unternehmen mit beta ähnlich ProMIS Neurosciences